Reed Jobs: GLP-1 Drugs Could Become a Weapon Against Cancer

Reed Jobs' oncology VC Yosemite passed its $350 million second-round target. He calls GLP-1s 'some of the most important drugs' ever, citing a 17% lower cancer hazard in a JAMA study.